The American Society of Clinical Oncology (ASCO) has reviewed complications associated with immune checkpoint inhibitor therapy.
Patient selection: aplastic anemia following therapy with immune checkpoint inhibitor
Parameters:
(1) absolute neutrophil count per µL
(2) platelet count per µL
(3) reticulocyte count per µL
(4) bone marrow
|
ANC
|
Platelet Count
|
Reticulocyte Count
|
Bone Marrow
|
Grade
|
|
>= 500
|
>= 20,000
|
>= 20,000
|
hypocellular; cellularity < 25%
|
G1 (mild)
|
|
< 500
|
< 20,000
|
NA
|
hypocellular; cellularity < 25%
|
G2 (moderate)
|
|
< 500
|
NA
|
< 20,000
|
hypocellular; cellularity < 25%
|
G2 (moderate)
|
|
NA
|
< 20,000
|
< 20,000
|
hypocellular; cellularity < 25%
|
G2 (moderate)
|
|
< 200
|
< 20,000
|
< 20,000
|
hypocellular; cellularity < 25%
|
G3 or G4 (severe)
|
Differential diagnosis:
(1) other causes of aplastic anemia (infection, chemotherapy, other)
